Bias, spin, and misreporting: time for full access to trial protocols and results
- PMID: 19067481
- PMCID: PMC2586359
- DOI: 10.1371/journal.pmed.0050230
Bias, spin, and misreporting: time for full access to trial protocols and results
Abstract
An-Wen Chan discusses the implications of a new study inPLoS Medicine that suggests that the randomized trial literature is skewed towards reporting favorable results.
Conflict of interest statement
References
-
- McHenry LB, Jureidini JN. Industry-sponsored ghostwriting in clinical trial reporting: A case study. Account Res. 2008;15:152–167. - PubMed
-
- Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: Selective reporting of study 329. Int J Risk Safety Med. 2008;20:73–81.
-
- Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation. JAMA. 2008;299:1813–1817. - PubMed
-
- Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med. 2006;354:1193. - PubMed
-
- Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, et al. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet. 2004;363:1341–1345. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources